

Atezolizumab IMspire150

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



QoL data pending



Serious and disabling adverse effects




Other adjustments



Atezolizumab IMspire150

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Skin Cancers
 Therapeutic Indication: Treatment for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma
 Experimental Arm: Atezolizumab + Cobimetinib + vemurafenib
 Control Arm: Placebo + cobimetinib + vemurafenib

